GV.PA stock €0.0018 on 16 Feb 2026: intraday most active trade, watch volume spike

GV.PA stock is trading at €0.0018 intraday on 16 Feb 2026, up 5.88% on heavy activity that makes it one of the most active small-caps on EURONEXT today. Volume sits at 38,489,238 shares versus an average of 14,217,513, giving a relative volume of 2.71 and signalling strong intraday interest. Investors are watching trading vs the 50-day average price of €0.00484 and the 200-day average €0.01399 as short-term traders dominate flows.

GV.PA stock intraday snapshot and trading metrics

Genomic Vision SA (GV.PA) on EURONEXT opened at €0.0018, with a day low of €0.0015 and a day high of €0.0020. Market cap is €693,191, shares outstanding 385,105,984, and current volume 38,489,238 which is more than double the 50-day average. The intraday move connects to very low liquidity and high relative volume, typical for micro-cap biotech listings.

Fundamentals and valuation for GV.PA stock

Genomic Vision reports trailing EPS -0.11 and a negative PE ratio (approx -0.016), reflecting sustained losses. Price-to-sales sits at 0.47 and EV-to-sales at 1.60, while cash per share is 0.00557 and current ratio is 0.91, indicating tight short-term coverage. Book value per share is negative, shareholders’ equity per share -0.00944, which highlights capital structure stress despite valuable IP in molecular combing technology.

GV.PA stock technicals and most-active trading context

Technically GV.PA is well below its 50-day and 200-day averages, with a year high of €0.0940 and year low €0.0014, showing extreme drawdown. The stock’s average volume is 14,217,513, today 38,489,238, making it a top intraday mover by volume on EURONEXT. For active traders this creates both rapid price moves and slippage risk; watch order book depth and wide bid-ask spreads.

Catalysts, recent news and sector backdrop for GV.PA stock

Genomic Vision’s product suite (FiberVision, FiberComb, FiberStudio) and partnerships with Quest Diagnostics and Institut Pasteur remain strategic assets. There is no company earnings headline today; the next recorded earnings announcement date in records was 28 Feb 2024. The Healthcare sector in Europe is steady, but larger peers show healthier margins and scale, making GV.PA a high-beta micro-cap play exposed to biotech funding cycles.

Risks and opportunities for GV.PA stock investors

Key risks include continued negative earnings, thin liquidity, high enterprise value relative to market cap (EV €2,369,191 vs market cap €693,191), and long cash conversion cycles. Opportunities originate from niche diagnostics demand, potential commercial deals for FiberVision, and any licensing or larger partner agreements that could materially improve cash flow. Position sizing and stop discipline are crucial for trading this stock.

Meyka AI rates GV.PA with a score out of 100 and forecast

Meyka AI rates GV.PA with a score out of 100: 62.42 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month price of €0.00600, compared with the current price €0.0018, implying an upside of 233.33%. A conservative downside scenario is €0.00100 (implied -44.44%). Forecasts are model-based projections and not guarantees. Sources: Genomic Vision website and related market coverage on Seeking Alpha.

Final Thoughts

GV.PA stock is an intraday most-active micro-cap on EURONEXT at €0.0018 with a volume surge to 38,489,238 shares that is drawing short-term traders. Fundamentals show negative EPS -0.11, tight liquidity, and negative book value per share, which argue for caution. Our Meyka AI grade (Score 62.42, Grade B, Suggestion: HOLD) frames GV.PA as a speculative hold: the technology and partnerships provide upside if a material commercial or licensing deal occurs, but funding and execution risk remain high. For risk-tolerant investors, the Meyka AI forecast 12-month target €0.00600 implies 233.33% upside from today’s price, while a conservative bear target of €0.00100 shows potential downside. Use small position sizes, monitor intraday liquidity, and treat this as a high-volatility trading vehicle rather than a diversified core holding. Meyka AI provides this as AI-powered market analysis and not investment advice; conduct your own research before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.